Skip to main content

Table 1 Charecteristics of SS, AS, S/βThal patients and controls. Data are presented as mean ± SD for the age and hematological data and frequency for sex and clinical complications

From: Factor V Leiden G1691A and prothrombin G20210A mutations among Palestinian patients with sickle cell disease

  AS (n = 25) SS (n = 59) S/βThal (n = 33) Controls (n = 118)
Sex, F/M 11/14 29/30 15/18 41/77
Age, years 21.2 ± 9.1 16 ± 9.9 15.1 ± 5.1 20.6 ± 5.5
Hematological data
 Hb (mg/dL) 12.9 ± 1.67 8.4 ± 1.09 8.32 ± 1.33 14.1 ± 1.58
 MCV (fL) 81.4 ± 7.39 87.4 ± 8.0 69.16 ± 7.91 85.2 ± 4.08
 MCH (pg) 26.78 ± 2.91 28.7 ± 2.88 23.34 ± 3.41 31.1 ± 2.76
 HbF (%) 1.1 ± 0.63 5.14 ± 3.3 7.98 ± 3.43 0.9 ± 0.23
 HbS (%) 36.3 ± 6.1 86.6 ± 7.4 69.8 ± 10.56 0
 Hb A2 (%) 2.61 ± 0.41 2.1 ± 0.52 4.46 ± 0.74 2.4 ± 0.52
Clinical complications
 DVT 0 0 3 0
 Stroke 0 3 1 0
 Priapism 0 2 0 0
 Leg ulcers 0 9 0 0
 AVN 0 5 2 0
  1. Hb hemoglobin, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, HbF hemoglobin F, HbS hemoglobin S, HbA2 hemoglobin A2. AS Sickle cell trait, SS Sickle cell anemia, S/βThal Sickle β-thalassemia, DVT deep vein thrombosis, AVN avascular bone necrosis